DelveInsight’s “Tenosynovial Giant Cell Tumor Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Tenosynovial Giant Cell Tumor, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumor Market Trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Explore the intricate details of the Tenosynovial Giant Cell Tumor Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Tenosynovial Giant Cell Tumor Market Forecast. Click here to stay ahead in healthcare innovation @ Tenosynovial Giant Cell Tumor Market Size
Key Takeaways from the Tenosynovial Giant Cell Tumor Market Report
- May 2024:- Deciphera Pharmaceuticals LLC– A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor. This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.
- May 2024:- SynOx Therapeutics Limited– A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour. The study consists of two parts. In Part 1, eligible subjects will be assigned in a 2:1 ratio to receive either emactuzumab or matching placebo in a double-blind fashion, that will be administered in total 5 times as an intravenous (i.v.) infusion once every 2 weeks. This will be followed by an observation period of 3 months leading to a total duration of 24 weeks in Part 1.
- According to DelveInsight, the total Tenosynovial Giant Cell Tumor Incident population in the 7MM was estimated to be 33,577 cases in 2021, which is anticipated to increase in the forecasted period.
- The total Tenosynovial Giant Cell Tumor incident population in EU4and the UK was 43% of the total incident population among the 7MM in2021.
- According to DelveInsight analysis in the US, the gender-specific incidence of Diffuse Tenosynovial Giant Cell Tumors (D-TSGCTs) were equal for males and females, whereas for Localized Tenosynovial Giant Cell Tumors (LTSGCTs) the incidence of females were higher than male incident cases.
- The leading Tenosynovial Giant Cell Tumor Companies such as Deciphera Pharmaceuticals, SynOx Therapeutics (Celleron Therapeutics), AmMax Bio, Abbisko Therapeutics Co, Ltd, and others.
- Promising Tenosynovial Giant Cell Tumor Therapies such as AMB-05X, Emactuzumab, Nilotinib, Vimseltinib, Pimicotinib(ABSK021), and others.
Delve deep into the Tenosynovial Giant Cell Tumor Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Tenosynovial Giant Cell Tumor Market Forecast. Click here to shape the future @ Tenosynovial Giant Cell Tumor Epidemiology Insights
Tenosynovial Giant Cell Tumor Overview
Tenosynovial giant cell tumors (TSGCTs) are rare, locally aggressive, typically benign neoplasms of joints, bursae, and tendon sheaths. TSGCTs can be roughly divided into localized and diffused types. Giant cell tumor often on sheath is the most common form of TSGCT. They are caused by a translocation of certain parts of chromosomes 1 and 2 causing the cells to overproduce a protein called colony-stimulating factor-1 or CSF-1. There are no environmental, genetic, occupational, lifestyle, demographic or regional risk factors that have been conclusively shown to be involved with the development of these tumors.
Tenosynovial Giant Cell Tumor Epidemiology Insights
- Tenosynovial Giant Cell Tumor Incident cases
- Tenosynovial Giant Cell Tumor Gender-specific Incident cases
- Tenosynovial Giant Cell Tumor Tumor Localization
- Tenosynovial Giant Cell Tumor Growth Pattern-specific Incident cases
Navigate the complexities of the Tenosynovial Giant Cell Tumor Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Tenosynovial Giant Cell Tumor Market Forecast. Click here to get more insights @ Tenosynovial Giant Cell Tumor Treatment Market
Tenosynovial Giant Cell Tumor Market Insights
Surgery is the mainstay and frontline of treatment for TGCT. TGCT is typically treated with synovectomy, removing the involved area of the lining. In Synovectomy technique, the damaged synovium is completely removed, and it is performed either arthroscopic or open surgery. Arthroscopic surgery involves creating a much smaller incision through which very small instruments are placed. These instruments include a tiny camera that allows the surgeon to see within the diseased joint and surgically remove the diseased tissue.
Tenosynovial Giant Cell Tumor Market Drug Market
An increase in the Tenosynovial Giant Cell Tumor incident cases and the expected launch of emerging therapies will boost the market in the forecasted period [2024–2034]. Emerging novel therapies like AMB-05X, Vimseltinib and others are awaiting approval. These emerging therapies are in the mid and late phases of clinical trials, holding significant promise and potential to manage the disease burden.
Tenosynovial Giant Cell Tumor Emerging Therapy Assessment
Tenosynovial Giant Cell Tumor companies across the globe are diligently working toward developing novel treatment therapies with a considerable amount of success over the years. Key players, such as AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others are developing drugs to treat Tenosynovial Giant Cell Tumor.
Tenosynovial Giant Cell Tumor Drugs Uptake
- AMB-05X is a human monoclonal antibody against the CSF1R, in development by Amgen, and is the only pharmacological treatment administered locally and directly at the tumor site for tenosynovial giant cell tumor (TGCT). Positive results from a Phase II proof-of-concept study demonstrated that it could offer physicians and patients with a more convenient and potentially much safer treatment option, enabling its potential application in a much larger TGCT patient segment unserved by the systemically administered agents. AMB-05X has also received Fast Track and PRIME designations from the FDA and European Medicines Agency, respectively. It is currently in Phase II of its clinical development.
- Vimseltinib is an investigational, in development by Deciphera Pharmaceuticals LLC, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R. It is currently been studied in an international, multicenter, open-label Phase I/II study to assess its safety, efficacy, pharmacokinetics, and pharmacodynamics in patients with advanced tumors and TGCT. Further the company is advancing vimseltinib in a pivotal Phase III study in patients with TGCT, which is currently recruiting candidates for its clinical trial.
Unlock insights into the Tenosynovial Giant Cell Tumor Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Tenosynovial Giant Cell Tumor Market Forecast. Click here @ Tenosynovial Giant Cell Tumor Market Drivers and Barriers
Scope of the Tenosynovial Giant Cell Tumor Market Report
- Coverage- 7MM
- Tenosynovial Giant Cell Tumor Companies- Deciphera Pharmaceuticals, SynOx Therapeutics (Celleron Therapeutics), AmMax Bio, Abbisko Therapeutics Co, Ltd, and others.
- Tenosynovial Giant Cell Tumor Therapies- AMB-05X, Emactuzumab, Nilotinib, Vimseltinib, Pimicotinib(ABSK021), and others.
- Tenosynovial Giant Cell Tumor Market Dynamics: Tenosynovial Giant Cell Tumor Market Drivers and Tenosynovial Giant Cell Tumor Market Barriers
- Tenosynovial Giant Cell Tumor Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Tenosynovial Giant Cell Tumor Unmet Needs, KOL’s views, Analyst’s views, Tenosynovial Giant Cell Tumor Market Access and Reimbursement
Gain a strategic edge in the Tenosynovial Giant Cell Tumor Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Tenosynovial Giant Cell Tumor Market Forecast. Click here to lead in advancements @ Tenosynovial Giant Cell Tumor Clinical Trials Assessment
Table of Content
1. Key Insights
2. Report Introduction
3. TGCT Market Overview at a Glance
4. Executive Summary of Tenosynovial Giant Cell Tumor (TGCT)
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
13. Market Access and Reimbursement
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/